Search

N, S co-doped graphene (NSG) has been synthesized by using graphene oxide, cyanamide and sodium sulphide as a source of C, N and S respectively. Due to its excellent electronic properties and stability, NSG has been used as an adsorbent for methylene blue (MB) removal from aqueous solution. Adsorption efficiencies of Graphene, N-doped graphene, S-doped graphene and NSG were compared during the study and it was found that NSG was the most efficient material for the adsorption of MB. The study was carried out in the UV-visible region by observing the changes in absorbance. NSG has excellent properties to adsorb the MB dye with a removal efficiency of 93.76±0.2%. Additionally, desorption studies were also carried out using 0.1 M cetylpyridinium chloride as cationic surfactant and the desorption% was found to be 50.28±0.1%, signifying its reusability as an adsorbent. This indicates that NSG opens a new window for the design of heteroatom-doped carbon material as well as its application in the adsorption studies. Accordingly, the synthesized material will be employed for wastewater treatment as a reusable adsorbent of MB in the near future with high efficiency and appreciable stability. In addition, the material has several other future applications such as electrode material for supercapacitor battery, sensor, adsorbent for metal ions and biomolecules, etc.

Biophenols (BPs) are one of the natural phytochemical products, found majorly in fruits, cereals, vegetables and beverages. BPs has gotten a lot of press in recent years due to their abundance in nature as well as biological activities. Furthermore, they are potential targets for food and pharmaceutical industries. Many extraction techniques are presented in this paper. Among all the techniques presented in this paper, pressing and solvent extraction methods are considered as traditional techniques while supercritical fluid extraction, solid phase microextraction, microwave assisted extraction, and Enzyme assisted extraction are considered as advanced techniques. The fundamentals on analysis of BPs employing different analytical instrumental techniques for qualitative and quantitative determination in environmental samples are also discussed. Only a few specific polyphenolic chemicals have had their safety and health claims formally sanctioned, therefore recent international regulatory laws are examined. In addition to the health claims and marketing of polyphenols as a functional food, the effects of food processing on polyphenol bioavailability are investigated. A number of investigational agents or polyphenol-rich content like HQC/QC and honey, from photochemistry are being also explored for recent antiviral treatment of COVID-19 and their treatment strategies. The day-by-day advancement in the analytical methodologies for BPs detection provides the platform to find out the health favorable components. This review focuses on the various extraction techniques, structure identification of plant extracts and quantification of BPs.

Background: Little is known about variations in care and outcomes of patients undergoing surgical repair for type A aortic dissection(TAAD). We aim to investigate decade-long trends in TAAD surgical repair in England. Methods: Retrospective review of the National Adult Cardiac Surgery Audit, which prospectively collects demographic and peri‑operative information for all major adult cardiac surgery procedures performed in the UK. We identified patients undergoing surgery for TAAD from January 2009-December 2018, reviewed trends in operative frequency, patient demographics, and mortality. Findings: Over the 10-year period,3,680 TAAD patients underwent surgical repair in England. A doubling in the overall number of operations conducted in England was observed (235 cases in 2009 to 510 in 2018). Number of procedures per hospital per year also doubled(9 in 2009 to 23 in 2018). Overall, in-hospital mortality was 17.4% with a trend toward lower mortality in recent years(23% in 2009 to 14.7% in 2018). There was a significant variation in operative mortality between hospitals and surgeons. We also found that most patients presented towards the middle of the week and during winter. Interpretation: Surgery is the only treatment for acute TAAD but is associated with high mortality. Prompt diagnosis and referral to a specialist center is paramount. The number of operations conducted in England has doubled in 10 years and the associated survival has improved. Variations exist in service provision with a trend towards better survival in high volume centers. Funding: British Heart Foundation and NIHR Biomedical Research center(University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol).

Background: There is little known about how payer status impacts clinical outcomes in a universal single-payer system such as the UK National Health Service (NHS). The aim of this study was to evaluate the relationship between payer status (private or public) and clinical outcomes following cardiac surgery from NHS providers in England. Methods: The National Adult Cardiac Surgery Audit (NACSA) registry was interrogated for patients who underwent adult cardiac surgery in England from 2009 to 2018. Information on socioeconomic status were provided by linkage with the Iteration of the English Indices of Deprivation (IoD). The primary outcome was in-hospital mortality. Secondary outcomes included incidence of in-hospital postoperative cerebrovascular accident (CVA), renal dialysis, sternal wound infection, and re-exploration. To assess whether payer status was an independent predictor of in-hospital mortality, binomial generalized linear mixed models (GLMM) were fitted along with 17 items forming the EuroSCORE and the IoD domains. Findings: The final sample consisted of 280,209 patients who underwent surgery in 31 NHS hospitals in England from 2009 to 2018. Of them, 5,967 (2.1%) and 274,242 (97.9%) were private and NHS payers respectively. Private payer status was associated with a lower risk of in-hospital mortality (OR 0.79; 95%CI 0.65 – 0.97;P = 0.026), CVA (OR 0.77; 95%CI 0.60 – 0.99; P = 0.039), need for re-exploration (OR 0.84; 95%CI 0.72 – 0.97; P = 0.017) and with non-significant lower risk of dialysis (OR 0.84; 95%CI 0.69 – 1.02; P = 0.074). Private payer status was found to be independently associated with lower risk of in-hospital mortality in the elective subgroup (OR 0.76; 95%CI 0.61 – 0.96; P = 0.020) but not in the non-elective subgroup (OR 1.01; 95%CI 0.64 – 1.58; P = 0.976). Interpretation: In conclusion, using a national database, we have found evidence of significant beneficial effect of payer status on hospital outcomes following cardiac surgery in favour of private payers regardless their socioeconomic factors.